A dual GLP-1-estrogen conjugate (GE) designed to selectively deliver estrogen to GLP-1R + cells induced substantial weight loss in mice without evidence of systemic estrogenic effects, as assessed by uterine weight and growth of estrogen-dependent breast cancer xenografts (Kanoski et al., 2011)
Should it eventually win approval, the drug could offer a more convenient option for some potential users while also illustrating that theres more than one way to treat obesity
The proportion of participants achieving clinically meaningful weight reduction was also significantly higher with semaglutide: 79 percent achieved at least 5 percent weight loss 63 percent achieved at least 10 percent 50 percent achieved at least 15 percent 30 percent achieved at least 20 percent These outcomes were accompanied by significant improvements in physical function, as measured by a validated quality-of-life tool
Role of l-carnitine and oleate in myogenic differentiation: implications for myofiber regeneration
Endosomal binding CHO-SNAP-GLP-1R cells were labeled with 5 M BG-SS-biotin, a cleavable SNAP-Surface probe containing a disulfide bond between O 6 -benzylguanine and biotin moieties (a gift from New England Biolabs) plus streptavidin-terbium cryptate (Cisbio, 0.24 g ml 1 active moiety)
Other randomized control trials show similar results, too, with the best results coming from supervised exercise exceeding the 150-minute/week guideline (Lundgren, 2021